ANTI-IDIOTYPIC ANTIBODY VACCINES FOR HPV INFECTION

用于 HPV 感染的抗独特型抗体疫苗

• 批准号: 3200816
• 负责人: NEIL D CHRISTENSEN
• 金额: $ 12.41万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-09-30 至 1995-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3200816
• 关键词: antiidiotype antibody; athymic mouse; disease /disorder model; enzyme linked immunosorbent assay; epitope mapping; human papillomavirus; human tissue; immunization; laboratory mouse; laboratory rabbit; monoclonal antibody; neutralizing antibody; rabbit papillomavirus; statistics /biometry; viral vaccines; virion; virus antigen; virus diseases

Human papillomavirus (HPV) gene products are present in most cervical and many anogenital carcinomas. The early lesions caused by these viruses have been shown to progress to carcinomas in some individuals, which demonstrates that certain HPV types play a role in the development of these tumors. A vaccine for protection against HPV infection therefore may decrease the incidence of cervical and anogenital cancers. Such a vaccine is currently unavailable. Our long-term goal is to develop monoclonal anti-idiotypic antibodies (anti-Ids) that antigenically mimic neutralizing epitopes on HPVs and which stimulate a host protective response against HPV infection. The Specific Aims are to use sets of monoclonal antibodies which neutralize HPV type 11 (HPV-11) and cottontail rabbit papillomavirus (CRPV) as antigen to develop a panel of monoclonal anti-Ids. These monoclonal anti-Ids will be tested as (i) immunogens in rabbits and mice for the induction of virus-neutralizing antibodies, and (ii) as probes for the detection of neutralizing antibodies in virus-infected humans and rabbits. We will use two papillomavirus animal model systems for these studies. The athymic mouse xenograft system utilizing HPV-11 infected human foreskin tissue will be used as a model for infection by a human genital papillomavirus type. The CRPV/domestic rabbit system will be used as an animal model which allows for controlled immunizations and deliberate viral challenge; neither of which are possible in the xenograft system. The two papillomavirus models will provide complementary positive and negative control reagents in the form of non-cross-reactive neutralizing and anti-Id monoclonal antibodies for each viral system. This is because these two viruses are host specific in their infectivity, and because the neutralizing epitopes as detected by antibodies are virus-specific.

人乳头瘤病毒(HPV)基因产物存在于大多数宫颈和 许多肛门生殖器癌。由这些病毒引起的早期损害 已经被证明在一些人中进展为癌症，这 证明某些类型的人乳头瘤病毒在人类免疫缺陷病毒的发展中起作用 这些肿瘤。因此，一种预防HPV感染的疫苗 可能会降低宫颈癌和肛门癌的发病率。这样的一个 目前还没有疫苗。 我们的长期目标是开发抗独特型单抗。 (抗-Ids)在HPV和HPV上模拟中和表位 刺激宿主对HPV感染的保护性反应。这个 特定的目标是使用一组能够中和 人乳头瘤病毒11型(HPV-11)和棉尾兔乳头瘤病毒(CRPV) 抗原，以开发一组单克隆性抗ID。这些单抗 抗-IDs将作为(I)兔和小鼠的免疫原进行测试 诱导病毒中和抗体，以及(Ii)作为 病毒感染人群中中和抗体的检测 兔子。 我们将使用两种乳头瘤病毒动物模型系统进行这些研究。 HPV-11感染人裸鼠异种移植系统的建立 包皮组织将被用作人类生殖器感染的模型 乳头瘤病毒型。CRPV/家兔系统将被用作 动物模型，允许控制免疫和刻意 病毒挑战；这两者在异种移植系统中都不可能实现。 这两种乳头瘤病毒模型将提供互补的阳性和 无交叉反应中和形式的阴性对照试剂 以及针对每个病毒系统的抗ID单抗。这是因为 这两种病毒在传染性上是宿主特有的，而且因为 抗体检测到的中和表位是病毒特异性的。